Fosinopril

Evidence Level: L5

Predicted Indications: 4

Fosinopril

Pharmacist Assessment Report

Fosinopril: Malignant hypertensive renal disease

One-Sentence Summary

Fosinopril is an ACE inhibitor originally used to treat hypertension. The TxGNN model predicts it may be effective for malignant hypertensive renal disease, but there are currently 0 clinical trials and 0 directly relevant publications supporting this direction, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Malignant hypertensive renal disease
TxGNN Prediction Score	0.9987
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 6 of 6)
Number of DINs	6 (marketed: 6)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the data compiled for this report. Based on known information, fosinopril belongs to the ACE inhibitor class. These drugs lower angiotensin II and therefore blood pressure, and its efficacy in hypertension is established.

Renovascular hypertension depends heavily on the renin-angiotensin system, so blocking this pathway is mechanistically plausible. The high TxGNN score most likely reflects the close similarity between this disease and the approved hypertension indication, not new clinical evidence.

There is an important safety caveat. ACE inhibitors can precipitate acute renal failure in patients with bilateral renal artery stenosis or stenosis in a solitary kidney. This is a major concern for this particular predicted indication.

The other predictions follow the same pattern:

Malignant hypertensive renal disease (0.9987): a plausible extension of the hypertension indication, since blocking the renin-angiotensin system may lower blood pressure and pressure inside the kidney’s filtering units. No supporting studies were found.
Pulmonary hypertension (two predictions, 0.9987): ACE inhibitors have not shown reliable benefit here, and systemic vasodilators may worsen oxygenation. The prediction appears to be driven by shared network features.
Braddock syndrome (0.9981): no clear mechanistic rationale could be identified.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

For the top prediction (malignant hypertensive renal disease), no related literature is available.

The only publications retrieved were for the third-ranked prediction, pulmonary hypertension owing to lung disease and/or hypoxia. Neither supports efficacy:

PMID	Year	Type	Journal	Key Findings
9923037	1998	Case report	Revue des maladies respiratoires	Two patients taking enalapril or fosinopril for hypertension developed hypoxic eosinophilic pneumonia with sub-acute respiratory failure. This is a safety signal, not efficacy evidence.
31105790	2019	Preclinical/Bioinformatics	Experimental and Therapeutic Medicine	Gene-expression analysis in mouse mesangial cells in a diabetic nephropathy context. It is unrelated to pulmonary hypertension.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02247803	TEVA-FOSINOPRIL	Not specified	Not specified
02266008	APO-FOSINOPRIL	Not specified	Not specified
02459396	FOSINOPRIL	Not specified	Not specified
02266016	APO-FOSINOPRIL	Not specified	Not specified
02247802	TEVA-FOSINOPRIL	Not specified	Not specified

All 6 licences are valid single-ingredient products with none cancelled. The table shows the first 5.

Safety Considerations

Disease-level contraindication signals (from the knowledge graph, not from label text):
- Kidney disease and liver disease
- Pancreatitis and gallbladder disease
- Angioedema, including hereditary, acquired and RAAS-blocker-induced forms
- Systemic lupus erythematosus and other connective tissue disease
- Diabetes mellitus and diabetic ketoacidosis
- Potassium deficiency and hyperparathyroidism
- Neutropenia and agranulocytosis
- Aortic stenosis and aortic valve disease
- Hypotensive disorder
- Hepatic coma and hepatic encephalopathy
- Bone disease
Drug Interactions (100 interactions recorded; examples shown):
- Major: potassium bicarbonate and potassium citrate, which carry a risk of raised potassium.
- Moderate: corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), aspirin, and glucose-lowering drugs (metformin, alogliptin, saxagliptin, canagliflozin, dapagliflozin, empagliflozin, chlorpropamide). Others include bupropion, morphine, dronabinol, and bowel-preparation products.
Specific to the predicted indication: ACE inhibitors may cause acute renal failure in bilateral renal artery stenosis or stenosis in a solitary kidney. Renal function and potassium monitoring would be required.

The package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on the model score, with no clinical trials and no supporting literature (Evidence Level L5). The renal safety risk specific to renovascular disease is substantial, and the package insert safety information has not yet been reviewed.

To proceed, the following is needed:

The Health Canada package insert, to complete warnings and contraindications review (this currently blocks safety screening)
Mechanism of action data (for example from DrugBank)
A targeted literature search on ACE inhibitors in renovascular and malignant hypertension, including renal safety in renal artery stenosis
An assessment of whether the existing approved hypertension indication already covers severe or malignant forms
A review of the biological plausibility of the lower-ranked predictions (pulmonary hypertension and Braddock syndrome) before any research question is framed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.